Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1136 - Antiviral Therapy Improves Outcomes after Radiofrequency Ablation for HBV-related Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Supportive Care and Symptom Management;  Surgical Oncology

Tumour Site

Hepatobiliary Cancers

Presenters

Kui Wang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

K. Wang, F. Shen, J. Liu, Z. Yan, J. Li, Y. Xia, L. Shi, G. Qian, Z. Lu, Y. Chen, X. Wan, M. Wu, Y. Zhang

Author affiliations

  • Hepatobiliary Surgery, Eastern Hepatobiliary Surgical Hospital(EHSH),2nd Military Medical University, 200438 - Shanghai/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1136

Background

We intended to explore hepatitis B virus (HBV) reactivation after percutaneous radiofrequency ablation (PRFA) for HBV-related hepatocellular carcinoma (HCC) and the impact of antiviral therapy (AVT) on post-PRFA outcomes.

Methods

Data on 538 consecutive patients who underwent PRFA for HBV-related early HCC at the Eastern Hepatobiliary Surgery Hospital between 2007 and 2011 were studied. Propensity score matching (PSM) analysis was used to compare the outcomes between the study groups. Recurrence free survival (RFS) and tumor recurrence were endpoints. Post-PRFA viral reactivation, hepatitis, and patterns of tumor recurrence were also observed. Logistic regression, Kaplan-Meier method and Cox proportional regression were used during the analysis.

Results

Viral reactivation developed in 10.8% of patients who underwent PRFA. Patients with HBV reactivation had higher 1-, 3-, and 5-year tumor recurrence rates than patients without viral reactivation after PRFA (46.9%, 81.6% and 81.6% vs 36.0%, 63.5% and 65.4%, P = 0.004). AVT reduced viral reactivation rate (P < 0.001) and decreased 1-,3-,5-year tumor recurrence rate when compared with the no-AVT (30.2%, 58.6% and 61.4% vs 44.1%, 72.6% and 73.0%, P = 0.001). The local recurrence of tumor after PRFA was only associated with tumor diameter (P = 0.010), however, viral reactivation (P = 0.015) and AVT (P < 0.001) were independent risk factors of intrahepatic distant recurrence.

Conclusions

HBV could be reactivated after PRFA. Viral reactivation and AVT had opposite impact on intrahepatic distant recurrence but not local tumor progression of HCC patients after PRFA.

Clinical trial identification

Legal entity responsible for the study

Feng Shen MD.

Funding

State Key Project on Infectious Diseases of China (2012ZX10002-011,016 to FS).

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.